Flibanserin (hydrochloride)

Flibanserin hydrochloride (BIMT-17 hydrochloride) is an orally active 5-HT1A receptor agonist and 5-HT2A receptor antagonist with binding affinities Ki of 1 nM and 49 nM, respectively. Flibanserin hydrochloride also binds to dopamine D4 receptors with a Ki of 4-24 nM. Flibanserin hydrochloride has antidepressant and anxiolytic effects and can be used in the study of hypoactive sexual desire disorder (HSDD)[1].

[1]El-Behairy, et al. "Insights into flibanserin oxidative stress degradation pathway: in silico–in vitro toxicity assessment of its degradates." New Journal of Chemistry 45.5 (2021): 2620-2630.|[2]Invernizzi, Roberto William, et al. "Flibanserin, a potential antidepressant drug, lowers 5‐HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5‐HT1A receptors." British journal of pharmacology 139.7 (2003): 1281-1288.|[3]Gelez, et al. "Brain neuronal activation induced by flibanserin treatment in female rats." Psychopharmacology 230 (2013): 639-652.|[4]Podhorna, et al. "Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety." British journal of pharmacology 130.4 (2000): 739-746.|[5]Gelman, et al. "Flibanserin for hypoactive sexual desire disorder: place in therapy." Therapeutic Advances in Chronic Disease 8.1 (2017): 16-25.